Paul Mischel, M.D.
Affiliations: | Pathology | University of California, San Diego, La Jolla, CA |
Area:
EGFR/PI3K/Akt/mTOR signaling networkWebsite:
http://www.ludwigcancerresearch.org/location/san-diego-branch/paul-s-mischel-labGoogle:
"Paul Mischel"Children
Sign in to add trainee| Feng Feng Liu | post-doc | UCSD | |
| Beatrice Gini | post-doc | UCSD | |
| Kenta Masui | post-doc | UCSD | |
| Tomoo Matsutani | post-doc | UCSD |
Collaborators
Sign in to add collaborator| National Brain Tumor Society | collaborator | National Brain Tumor Society |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Raeisi Dehkordi S, Wong IT, Ni J, et al. (2025) Breakage fusion bridge cycles drive high oncogene number with moderate intratumoural heterogeneity. Nature Communications. 16: 1497 |
| Tang J, Weiser NE, Wang G, et al. (2024) Enhancing transcription-replication conflict targets ecDNA-positive cancers. Nature. 635: 210-218 |
| Harachi M, Masui K, Shimizu E, et al. (2024) DNA hypomethylator phenotype reprograms glutamatergic network in receptor tyrosine kinase gene-mutated glioblastoma. Acta Neuropathologica Communications. 12: 40 |
| Dehkordi SR, Wong IT, Ni J, et al. (2023) Breakage fusion bridge cycles drive high oncogene copy number, but not intratumoral genetic heterogeneity or rapid cancer genome change. Biorxiv : the Preprint Server For Biology |
| Masui K, Mischel PS. (2023) Metabolic and epigenetic reprogramming in the pathogenesis of glioblastoma: Toward the establishment of "metabolism-based pathology". Pathology International. 73: 533-541 |
| Raviram R, Raman A, Preissl S, et al. (2023) Integrated analysis of single-cell chromatin state and transcriptome identified common vulnerability despite glioblastoma heterogeneity. Proceedings of the National Academy of Sciences of the United States of America. 120: e2210991120 |
| West TJ, Bi J, Martínez-Peña F, et al. (2023) A Cell Type Selective YM155 Prodrug Targets Receptor-Interacting Protein Kinase 2 to Induce Brain Cancer Cell Death. Journal of the American Chemical Society |
| Pecorino LT, Verhaak RGW, Henssen A, et al. (2022) Extrachromosomal DNA (ecDNA): an origin of tumor heterogeneity, genomic remodeling, and drug resistance. Biochemical Society Transactions |
| Chen PB, Fiaux PC, Zhang K, et al. (2022) Systematic discovery and functional dissection of enhancers needed for cancer cell fitness and proliferation. Cell Reports. 41: 111630 |
| Noorani I, Mischel PS, Swanton C. (2022) Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges. Nature Reviews. Clinical Oncology |